<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        311-212-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VALISTA 80 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Valista </strong>belongs to a class of medicines known as angiotensin II receptor antagonist, which help to control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase. <strong>Valista </strong>works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered.</p><p><strong>Valista 40 mg film-coated tablets can be used for three different conditions:</strong></p><p><strong>&bull;</strong> <strong>to treat high blood pressure in children and adolescents 6 to 18 years of age.</strong></p><p>High blood pressure increases the workload on the heart and arteries. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p><p>&bull; <strong>to treat adult patients after a recent heart attack (myocardial infarction)</strong>.</p><p>&ldquo;Recent&rdquo; here means between 12 hours to 10 days.</p><p>&bull;<strong> to treat symptomatic heart failure in adult patients</strong>.</p><p>Valista is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used or it may be used in addition to ACE inhibitors when beta blockers (another medication to treat heart failure) cannot be used. Heart failure symptoms include shortness of breath, and swelling of the feet and legs due to fluid build-up. It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.</p><p><strong>Valista 80 mg film-coated tablets can be used for three different conditions:</strong></p><p>&bull; t<strong>o treat high blood pressure in adult and children and adolescents 6 to 18 years of age.</strong></p><p>High blood pressure increases the workload on the heart and arteries. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a&nbsp;stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p><p><strong>&bull; to treat adult patients after a recent heart attack (myocardial infarction).</strong></p><p>&ldquo;Recent&rdquo; here means between 12 hours to 10 days.</p><p><strong>&bull; to treat symptomatic heart failure in adult patients.</strong></p><p>Valista is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used or it may be used in addition to ACE inhibitors when beta blockers (another medication to treat heart failure) cannot be used. Heart failure symptoms include shortness of breath, and swelling of the feet and legs due to fluid build-up. It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.</p><p><strong>Valista 160 mg film-coated tablets can be used for three different conditions:</strong></p><p><strong>&bull; to treat high blood pressure in adult and in children and adolescents 6 to 18 years of age.</strong></p><p>High blood pressure increases the workload on the heart and arteries. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p><p><strong>&bull; to treat adult patients after a recent heart attack (myocardial infarction). </strong></p><p>&ldquo;Recent&rdquo; here means between 12 hours and 10 days.</p><p><strong>&bull; to treat symptomatic heart failure in adult patients.</strong></p><p>Valista is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used or it may be used in addition to ACE inhibitors when beta blockers (another medication to treat heart failure) cannot be used. Heart failure symptoms include shortness of breath, and swelling of the feet and legs due to fluid build-up. It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.</p><p><strong>Valista 320 mg film-coated tablets can be used:</strong></p><p>-<strong> to treat high blood pressure in adults and in children and adolescents 8 to 18 years of age</strong>.</p><p>High blood pressure increases the workload on the heart and arteries. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Valista:</strong></p><p>- if you are<strong> allergic</strong> (hypersensitive) to valsartan, soya oil, peanut oil or any of the other i<strong>ngredients of Valista</strong>.&nbsp;</p><p>- if you have <strong>severe liver disease.</strong></p><p>- if you are <strong>more than 3 months pregnant</strong> (it is also better to avoid Valista in early pregnancy &ndash; see pregnancy section).</p><p><strong>If any of these apply to you, do not take Valista </strong></p><p><strong>Take special care with Valista</strong></p><p>- if you have liver disease.</p><p>- if you have severe kidney disease or if you are undergoing dialysis.</p><p>- if you are suffering from a narrowing of the kidney artery.</p><p>- if you have recently undergone kidney transplantation (received a new kidney).</p><p>- if you are treated after a heart attack or for heart failure, your doctor may check your kidney function.</p><p>- if you have severe heart disease other than heart failure or heart attack.</p><p>- if you are taking medicines that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. It may be necessary to check the amount of potassium in your blood at regular intervals.</p><p>- if you are below 18 years of age and you take Valista in combination with other medicines that inhibit the renin angiotensin aldosterone system (medicines that lower blood pressure), your doctor may check your kidney function and the amount of potassium in your blood at regular intervals.</p><p>- if you suffer from aldosteronism. This is a disease in which your adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of Valista is not recommended.</p><p>- if you have lost a lot of fluid (dehydration) caused by diarrhoea, vomiting, or high doses of water tablets (diuretics).</p><p>- you must tell your doctor if you think you are (or might become) pregnant. Valista is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section)</p><p><strong>If any of these apply to you, tell your doctor before you take Valista</strong></p><p><strong>Taking other medicines</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. The effect of the treatment can be influenced if Valista is taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or in some cases to stop taking one of the medicines. This applies to both prescription and non-prescription medicines, especially:</p><p>- other medicines that lower blood pressure, especially water tablets (diuretics).</p><p>- medicines that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p>- certain type of pain killers called non-steroidal anti-inflammatory medicines (NSAIDs)</p><p>- lithium, a medicine used to treat some types of psychiatric illness.</p><p><strong>In addition:</strong></p><p>- if you are being treated after a heart attack, a combination with ACE inhibitors (a medication to treat heart attack) is not recommended.</p><p>- if you are being treated for heart failure, a triple combination with ACE inhibitors and beta blockers (medications to treat heart failure) is not recommended.</p><p><strong>Taking Valista with food and drink</strong></p><p>You can take Valista with or without food. Swallow Valista with a glass of water.</p><p>Take Valista at about the same time each day.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>- <strong>You must tell your doctor if you think that you are (or might become) pregnant.</strong> Your doctor will normally advise you to stop taking Valista before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Valista Valista is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</p><p>- <strong>Tell your doctor if you are breast-feeding or about to start breast-feeding</strong>. Valista is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how Valista affects you. Like many other medicines used to treat high blood pressure, Valista may in rare cases cause dizziness and affect the ability to concentrate.</p><p><strong>Important information about some ingredients of Valista</strong></p><p>This medicine contains lactose, if you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product. Valista contains soya oil. If you are allergic to peanut or soya, do not take this medicinal product.</p><p>Valista contains Sunset yellow FCF (E110) which may cause allergic reactions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Valista exactly as your doctor has told you in order to get the best results and reduce the risk of side effects. You should check with your doctor or pharmacist if you are not sure. People with high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with the doctor even if you are feeling well.</p><p><strong>Children and adolescents (6 to 18 years of age) with high blood pressure</strong></p><p>In patients who weigh less than 35 kg the usual dose is 40 mg of valsartan once daily. In patients who weigh 35 kg or more the usual starting dose is 80 mg of valsartan once daily. In some cases your doctor may prescribe higher doses (the dose can be increased to 160 mg and to a maximum of 320 mg).</p><p><strong>Adult patients after a recent heart attack:</strong> After a heart attack the treatment is generally started as early as after 12 hours, usually at a low dose of 20 mg twice daily. You obtain the 20 mg dose by dividing the 40 mg tablet. Your doctor will increase this dose gradually over several weeks to a maximum of 160 mg twice daily. The final dose depends on what you as an individual patient can tolerate. Valista can be given together with other treatment for heart attack, and your doctor will decide which treatment is suitable for you.</p><p><strong>Adult patients with heart failure: </strong>Treatment starts generally with 40 mg twice daily. Your doctor will increase the dose gradually over several weeks to a maximum of 160 mg twice daily. The final dose depends on what you as an individual patient can tolerate. Valista can be given together with other treatment for heart failure, and your doctor will decide which treatment is suitable for you.</p><p><strong>Adult patients with high blood pressure: </strong>The usual dose is 80 mg daily. In some cases your doctor may prescribe higher doses (e.g. 160 mg or 320 mg). He may also combine Valista with an additional medicine (e.g. a diuretic).</p><p>&nbsp;</p><p><strong>If you take more Valista than you should </strong></p><p>If you experience severe dizziness and/or fainting, lay down and contact your doctor immediately. If you have accidentally taken too many tablets, contact your doctor, pharmacist, or hospital.</p><p><strong>If you forget to take Valista</strong></p><p>Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the dose you missed.</p><p><strong>If you stop taking Valista</strong></p><p>Stopping your treatment with Valista may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to. If you have further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Valista can cause side effects, although not everybody gets them.</p><p>These side effects may occur with certain frequencies, which are defined as follows:</p><p>- very common: affects more than 1 user in 10</p><p>- common: affects 1 to 10 users in 100</p><p>- uncommon: affects 1 to 10 users in 1,000</p><p>- rare: affects 1 to 10 users in 10,000</p><p>- very rare: affects less than 1 user in 10,000</p><p>- not known: frequency cannot be estimated from the available data.</p><p><strong>Some symptoms need immediate medical attention:</strong></p><p>You may experience symptoms of angioedema (a specific allergic reaction), such as</p><p>- swollen face, lips, tongue or throat</p><p>- difficulty in breathing or swallowing</p><p>- hives, itching</p><p><strong>If you get any of these, see a doctor immediately.</strong></p><p><strong>Other side effects include:</strong></p><p>&nbsp;</p><p><strong>Common:</strong></p><p>- dizziness</p><p>- low blood pressure with or without symptoms such as dizziness and fainting when standing up</p><p>- decreased kidney function (signs of renal impairment)</p><p><strong>Uncommon</strong>:</p><p>- angioedema (see section &ldquo;Some symptoms need immediate medical attention&rdquo;)</p><p>- sudden loss of consciousness (syncope)</p><p>- spinning sensation (vertigo)</p><p>- severely decreased kidney function (signs of acute renal failure)</p><p>- muscle spasms, abnormal heart rhythm (signs of hyperkalaemia)</p><p>- breathlessness, difficulty breathing when lying down, swelling of the feet or legs (signs of cardiac failure)</p><p>- headache</p><p>- cough</p><p>- abdominal pain</p><p>- nausea</p><p>- diarrhea</p><p>- tiredness</p><p>- weakness</p><p><strong>Not known: </strong></p><p>- allergic reaction with rash, itching and hives; symptoms of fever, swollen joints and joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms may occur (signs of serum sickness)</p><p>- purplish-red spots, fever, itching (signs of inflammation of blood vessels also called vasculitis)</p><p>- unusual bleeding or bruising (signs of thrombocytopenia)</p><p>- muscle pain (myalgia)</p><p>- fever, sore throat or mouth ulcers due to infections (symptoms of low level of white blood cells also called neutropenia)</p><p>- decrease of level of haemoglobin and decrease of the percentage of red blood cells in the blood (which can lead to anaemia in severe cases)</p><p>- increase of level of potassium in the blood (which can trigger muscle spasms and abnormal heart rhythm in severe cases)</p><p>- elevation of liver function values (which can indicate liver damage) including an increase of bilirubin in the blood (which can trigger yellow skin and eyes in severe cases)</p><p>- increase of level of blood urea nitrogen and increase of level of serum creatinine (which can indicate abnormal kidney function)</p><p>- low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and/or convulsions in severe cases)</p><p>The frequency of some side effects may vary depending on your condition. For example, side effects such as dizziness, and decreased kidney function, were seen less frequently in adult patients treated with high blood pressure than in adult patients treated for heart failure or after a recent heart attack.</p><p>Side effects in children and adolescents are similar to those seen in adults.</p><p><strong>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&minus; Do not store above 30&deg;C. Store in the original package in order to protect from light and moisture.</p><p>&minus; This medicinal product does not require any special storage conditions</p><p>&minus; Keep out of the reach and sight of children.</p><p>&minus; Do not use Valista after the expiry date which is stated on the carton, blister and bottle as EXP. The expiry date refers to the last day of that month.</p><p>&minus; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; The active substance is valsartan.</p><p>Each film-coated tablet contains 40 mg of valsartan.</p><p>Each film-coated tablet contains 80 mg of valsartan.</p><p>Each film-coated tablet contains 160 mg of valsartan.</p><p>Each film-coated tablet contains 320 mg of valsartan.</p><p>-&nbsp; The other ingredients are: tablet core: lactose monohydrate, cellulose microcrystalline, croscarmellose sodium, povidone K29-K32, talc, magnesium stearate, colloidal anhydrous silica; tablet coat: polyvinyl alcohol, macrogol 3350, talc, lecithin (contains soya oil) (E322), titanium dioxide (E171), yellow iron oxide (E172). yellow iron oxide (E172) red iron oxide (E172) [only for 80 mg and 160 mg]. iron oxide black (E172), sunset yellow FCF aluminium lake (E110) [only for 320 mg].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Valista 40 mg film-coated tablets: Yellow, oval, biconvex, film-coated tablets, 9 x 4.5 mm, 
with a scoreline on one side and marked with a "V" on the other. 
Valista 80 mg film-coated tablets: Pink, round, biconvex, film-coated tablets, 8 mm in 
diameter, with a scoreline on both sides and marked with a "V" on one side. 
Valista 160 mg film-coated tablets: Yellow, oval, biconvex, film-coated tablets, 15 x 6.5 mm, 
with a scoreline on one side and marked with a "V" on the other. 
Valista 320 mg film-coated tablets: Brown, oval, biconvex, film-coated tablets, 19 x 8.2 mm, 
with a scoreline on one side and sidescores and marked with a "V" on the other.


Pack sizes
PVC/PE/PVDC Al Blister and OPA/AL/PVC Blister. 
Each pack contains: 7, 14, 28, 56, 98 and 280 tablets. 
Not all pack sizes may be marketed. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by:</p><p>SPIMACO</p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp;</p><p>Medical Appliance Corporation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ڤاليستا ھو دواء ينتمى إلى مجموعة من اSدوية التى تسمى مضادات مستقبل أنجيوتنسين - II&nbsp;والتى تساعد على التحكم فى ارتفاع ضغط الدم . أنجيوتنسين -II ھى مادة يتم إنتاجھا عن طريق الجسم والتى تسبب تضيق في الاوعية الدموية , مما ً يسبب ارتفاع ضغط الدم. ڤاليستا يعمل على إبطال مفعول مادة أنجيوتنسين&nbsp; -II بذلك ارتخاء فى الاوعية الدموية&nbsp; وانخفاض ضغط الدم</p><p><strong>أقراص ڤاليستا 40 ملجم المغطاة بطبقة رقيقة يمكن أن تستخدم فى ثلاث حاIت مختلفة : </strong></p><p><strong>&bull; لعلاج ارتفاع ضغط الدم عند الاطفال والمراھقين فيما بين 6 إلى 18 سنة من العمر </strong>.</p><p>ارتفاع ضغط الدم يزيد من عبء العمل على القلب والشرايين. إذا لم يعالج فإنه من الممكن أن يلحق الضرر بالاوعية الدموية فى المخ والقلب والكلى ومن ثم قد يؤدي إلى فشل القلب أوالسكتة الدماغية أو الفشل الكلوي . ارتفاع ضغط الدم يزيد من خطر الاصابة بالنوبات القلبية. خفض ضغط الدم إلى وضعه الطبيعي يقلل من خطر تطور ھذه الاضطرابات</p><p><strong>&bull; لعلاج المرضى البالغين بعد إصابتھم مؤخراً بأزمة قلبية</strong> (احتشاء عضلة القلب). حيث أن &quot;مؤخرا &quot; &quot; ھنا تعني ما بين12 ساعة إلى 10 أيام</p><p>&bull; <strong>لعلاج أعراض فشل القلب في المرضى البالغين</strong>. حيث أن ڤاليستا يستخدم فى حالة عدم إمكانية استخدام مجموعة من الادوية والتى تعرف باسم مثبطات الانزيم المحول للانجيوتنسين (ACE ( ) وھى أدوية تستخدم لعلاج فشل القلب) أو قد يستخدم بالاضافة إلى مثبطات ACE فى حالة عدم إمكانية استخدام الادوية المثبطة لمستقبلات بيتا (وھى أدوية أخرى تستخدم لعلاج فشل القلب)&nbsp;</p><p>أعراض فشل القلب تشمل الاتى: ضيق في التنفس و تورم في القدمين والساقين بسبب تراكم السوائل. يحدث ذلك فى حالة عدم استطاعة عضلة القلب بالقيام ب ضخ الدم بالقوة الكافية لتزويد كل الدم اللازم في جميع أنحاء الجسم</p><p><strong>أقراص ڤاليستا 80 ملجم المغطاة بطبقة رقيقة يمكن أن تستخدم فى ثلاث حاIت مختلفة :&nbsp;</strong></p><p>&nbsp;</p><p><strong>&bull; لعلاج ارتفاع ضغط الدم عند البالغين والاطفال والمراھقين فيما بين 6 إلى 18 سنة من العمر .</strong></p><p>ارتفاع ضغط الدم يزيد من عبء العمل على القلب والشرايين. إذا لم يعالج فإنه من الممكن أن يلحق الضرر بالاوعية الدموية فى المخ والقلب والكلى ومن ثم قد يؤدي إلى فشل القلب أوالسكتة الدماغية أو الفشل الكلوي . ارتفاع ضغط الدم يزيد من خطر الاصابة بالنوبات القلبية. خفض ضغط الدم إلى وضعه الطبيعي يقلل من خطر تطور ھذه الاضطرابات. ً</p><p><strong>&bull; لعلاج المرضى البالغين بعد إصابتھم مؤخراً بأزمة قلبية</strong> (احتشاء عضلة القلب). حيث أن &quot;مؤخرا&quot; ھنا تعني ما بين&nbsp; 12 ساعة إلى 10 أيام.</p><p><strong>&bull; لعلاج أعراض فشل القلب في المرضى البالغين</strong>. حيث أن ڤاليستا يستخدم فى حالة عدم إمكانية استخدام مجموعة من الادوية والتى تعرف باسم مثبطات الانزيم المحول للانجيوتنسين (ACE) (وھى أدوية تستخدم لعلاج فشل القلب) أو قد يستخدم باdضافة إلى مثبطات ACE فى حالة عدم إمكانية استخدام اSدوية المثبطة لمستقبلات بيتا (وھى أدوية أخرى تستخدم لعلاج فشل القلب ).</p><p>أعراض فشل القلب تشمل الاتى: ضيق في التنفس و تورم في القدمين والساقين بسبب تراكم السوائل. يحدث ذلك فى حالة عدم استطاعة عضلة القلب بالقيام ب ضخ الدم بالقوة الكافية لتزويد كل الدم اللازم في جميع أنحاء الجسم</p><p><strong>أقراص ڤاليستا 160 ملجم المغطاة بطبقة رقيقة يمكن أن تستخدم فى ثلاث حاIت مختلفة :</strong></p><p><strong>&bull; لعلاج ارتفاع ضغط الدم عند البالغين والاطفال والمراھقين فيما بين 6 إلى 18 سنة من العمر .</strong></p><p>ارتفاع ضغط الدم يزيد من عبء العمل على القلب والشرايين. إذا لم يعالج فإنه من الممكن أن يلحق الضرر بالاوعية الدموية فى المخ والقلب والكلى ومن ثم قد يؤدي إلى فشل القلب أوالسكتة الدماغية أو الفشل الكلوي . ارتفاع ضغط الدم يزيد من خطر الاصابة بالنوبات القلبية. خفض ضغط الدم إلى وضعه الطبيعي يقلل من خطر تطور ھذه الاضطرابات. ً</p><p><strong>&bull; لعلاج المرضى البالغين بعد إصابتھم مؤخراً بأزمة قلبية</strong> (احتشاء عضلة القلب). حيث أن &quot;مؤخرا&quot; ھنا تعني ما بين&nbsp; 12 ساعة إلى 10 أيام.</p><p><strong>&bull; لعلاج أعراض فشل القلب في المرضى البالغين</strong>. حيث أن ڤاليستا يستخدم فى حالة عدم إمكانية استخدام مجموعة من الادوية والتى تعرف باسم مثبطات الانزيم المحول للانجيوتنسين (ACE) (وھى أدوية تستخدم لعلاج فشل القلب) أو قد يستخدم باdضافة إلى مثبطات ACE فى حالة عدم إمكانية استخدام اSدوية المثبطة لمستقبلات بيتا (وھى أدوية أخرى تستخدم لعلاج فشل القلب ).</p><p>أعراض فشل القلب تشمل الاتى: ضيق في التنفس و تورم في القدمين والساقين بسبب تراكم السوائل. يحدث ذلك فى حالة عدم استطاعة عضلة القلب بالقيام ب ضخ الدم بالقوة الكافية لتزويد كل الدم اللازم في جميع أنحاء الجسم</p><p><strong>أقراص ڤاليستا 320 ملجم المغطاة بطبقة رقيقة يمكن أن تستخدم فى :&nbsp;</strong></p><p><strong>&bull; علاج ارتفاع ضغط الدم عند البالغين والاطفال والمراھقين فيما بين 8 إلى 18 سنة من العمر</strong> .</p><p>ارتفاع ضغط الدم يزيد من عبء العمل على القلب والشرايين. إذا لم يعالج فإنه من الممكن أن يلحق الضرر بالاوعية الدموية فى المخ والقلب والكلى ومن ثم قد يؤدي إلى فشل القلب أوالسكتة الدماغية أو الفشل الكلوي . ارتفاع ضغط الدم يزيد من خطر الاصابة بالنوبات القلبية. خفض ضغط الدم إلى وضعه الطبيعي يقلل من خطر تطور ھذه الاضطرابات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تقم بتناول أقراص ڤاليستا فى الحالات الاتية :</p><p>&bull; إذا كنت تعانى من فرط التحسس تجاه مادة ڤالسارتان أو زيت الصويا أو زيت الفول السودانى أو أى من المكونات الاخرى لاقراص ڤاليستا .</p><p>&bull; إذا كنت تعانى من مرض حاد بالكبد .</p><p>&bull; إذا كنت فيما بعد الشھر الثالث من الحمل (فإنه من الافضل أيضا تجنب تناول أقراص ڤاليستا فى المرحلة المبكرة من الحمل - انظري&nbsp;فقرة الحمل ).</p><p>&nbsp;</p><p>فى حالة انطباق أى من ھذه الحاIت المذكورة أعلاه عليك, لا&nbsp;تقم بتناول أقراص ڤاليستا</p><p>. ينبغى توخى الحذر أثناء العلاج بأقراص ڤاليستا فى الحاIت الاتية :&nbsp;</p><p>&bull; إذا كنت تعانى من مرض بالكبد .</p><p>&bull; إذا كنت تعانى من مرض حاد بالكلى أو تقوم بالغسيل الكلوى .</p><p>&bull; إذا كنت تعاني من تضيق الشريان الكلوي .</p><p>&bull; إذا كنت قد خضعت مؤخرا لعملية زراعة كلية (حصلت على كلية جديدة )&nbsp;&nbsp;</p><p>&bull; إذا كنت تخضع للعلاج بعد الاصابة بأزمة قلبية أو فشل القلب, فقد يلجأ طبيبك المعالج إلى إجراء فحص لوظائف الكلى لديك .</p><p>&bull; إذا كنت تعانى من أمراض حادة أخرى بالقلب غير فشل القلب أو الازمة القلبية .</p><p>&bull; إذا كنت تتناول أدوية تسبب زيادة مستوى البوتاسيوم فى الدم. والتى تشمل مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم أو الادوية المدخرة للبوتاسيوم والھيبارين. فقد يكون من الضرورى إجراء فحص لمستويات البوتاسيوم لديك فى الدم بشكل منتظم .</p><p>&bull; إذا كنت أقل من 18 سنة من العمر وتتناول أقراص ڤاليستا مع أدوية أخرى تعمل على تثبيط نظام رينين أنجيوتنسين ألدوستيرون (وھى أدوية تستخدم لخفض ضغط الدم , ) حينھا قد يلجأ طبيبك المعالج إلى إجراء فحص لوظائف الكلى وفحص كمية البوتاسيوم فى الدم لديك على فترات منتظمة .</p><p>&bull; إذا كنت تعاني من ألدوستيرونية. وھو مرض تقوم فيه الغدة الكظرية بإفراز كمية كبيرة من ھرمون الالدوستيرون. إذا كانت تنطبق عليك ھذه الحالة, فلا&nbsp;ينصح باستخدامك لاقراص ڤاليستا .</p><p>&bull; إذا تعرضت لفقد الكثير من السوائل ( الجفاف) بسبب التقيؤ أ والاسھال أو تناول جرعات عالية من أقراص الماء (مدرات البول ).</p><p>&bull;يجب عليك إخبار طبيبك المعالج إذا كنت &nbsp;تعتقدين بأنك ( أ<u>و ربما تصبحين</u>) حامل. حيث أنه لا ينصح باستخدام أقراص ڤاليستا فى المرحلة المبكرة من الحمل, ويجب عدم تناول أقراص ڤاليستا &nbsp;إذا كنت فيما بعد الشھر الثالث من الحمل, حيث أنه قد يسبب ضررا جسيما للجنين إذا ما تم تناوله فى ھذه المرحلة من الحمل(انظرى فقرة الحمل )</p><p><strong>فى حالة انطباق أى من ھذه الحاIت المذكورة أعلاه عليك, أخبر طبيبك المعالج قبل البدء فى تناول أقراص ڤاليستا</strong></p><p>&nbsp;<strong>تناول أدوية أخرى&nbsp;</strong>&nbsp;</p><p>&nbsp;أخبر طبيبك المعالج إذا كنت تتناول حاليا &nbsp;أو تناولت مؤخرا أى أدوية أخرى , بما فيھا تلك التى حصلت عليھا بدون وصفة طبية .</p><p>حيث أن تأثير العلاج قد يتأثر فى حالة تناول أقراص ڤاليستا مع بعض الادوية الاخرى. فقد يكون من الضرورى تغيير الجرعة أو اتخاذ بعض الاحتياطات أو فى بعض الحالات إيقاف استخدام أحد ھذه الادوية. ذلك ينطبق على كل من الادوية التى حصلت عليھا بوصفة طبية أو بدون وصفة طبية, وخاصة :&nbsp; &nbsp;</p><p>&bull; أدوية أخرى تستخدم لخفض ضغط الدم, خصوصا&nbsp;أقراص الماء (مدرات البول ).</p><p>&bull; أدوية أخرى تسبب زيادة مستوى البوتاسيوم فى الدم. والتى تشمل مكملات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم و الادوية المدخرة للبوتاسيوم والھيبارين .</p><p>&bull; نوع معين من مسكنات الالم والتى تعرف باسم مضادات الالتھاب غير الاستيرويدية (NSAIDs) .</p><p>&bull; الليثيوم, وھو دواء يستخدم لعلاج بعض الامراض النفسية</p><p><strong>بالاضافة إلى :</strong></p><p>&bull; إذا كنت تخضع <strong>للعلاج بعد الاصابة بأزمة قلبية</strong>, فإنه لا&nbsp;يوصى بالجمع مع<strong> مثبطات إنزيم ACE</strong>&nbsp;( وھى أدوية تستخدم لعلاج الازمة القلبية ).</p><p>&bull; إذا كنت تخضع للعلاج من <strong>فشل القلب</strong>, فإنه لا&nbsp;يوصى بالجمع مع مثبطات إنزيم ACE وحاصرات مستقبلات بيتا (وھى أدوية تستخدم لعلاج فشل القلب ).</p><p><strong>تناول أقراص ڤاليستا مع الطعام والشراب</strong></p><p>يمكن تناول أقراص ڤاليستا مع الطعام أو بدونه . قم بابتلاع قرص ڤاليستا مع كوب من الماء .</p><p>تناول أقراص ڤاليستا فى نفس الوقت تقريبا كل يوم .&nbsp;</p><p><strong>الحمل والرضاعة </strong></p><p>اسألى طبيبك المعالج أو الصيدلى للمشورة قبل البدء فى تناول أى أدوية .</p><p>&bull;&nbsp;<strong>&nbsp;يجب عليك إخبار طبيبك المعالج إذا كنت تعتقدين بأنك (أو ربما تصبحين) حامل </strong>. فمن الطبيعى أن ينصحك طبيبك المعالج بالتوقف عن تناول أقراص ڤاليستا قبل أن تصبحى حامل أو بمجرد معرفتك بالحمل, وسوف يقوم بوصف دواء اخر لك بدلا من&nbsp;ڤاليستا &nbsp;, حيث أنه لا&nbsp;يوصى باستخدام أقراص ڤاليستا فى المرحلة المبكرة من الحمل, ويجب عدم&nbsp;تناوله فيما بعد الشھر الثالث من الحمل, حيث انه يسبب ضررا جسيما للجنين اذا ما تم تناوله في مرحلة مابعد الشهر الثالث من الحمل</p><p><strong>&nbsp;&bull; يجب عليك إخبار طبيبك المعالج إذا كنت تقومين أو ستبدئين فى إرضاع طفلك طبيعيا.ً</strong></p><p>حيث أنه لايوصى باستخدام أقراص ڤاليستا للامهات أثناء الرضاعة الطبيعية, وقد يصف لك طبيبك المعالج دواء آخر إذا كنت ترغبين بالاستمرار فى الارضاع طبيعيا, خصوصا&nbsp; إذا كان طفلك حديث الولادة أو مولود قبل أوانه</p><p><strong>القيادة واستخدام الالات</strong></p><p>قبل البدء فى قيادة السيارة أو استخدام الادوات أو تشغيل الماكينات أو القيام بأى أ اعمال أخرى تستلزم التركيز, يجب أولا أن تعرف مدى تأثير أقراص ڤاليستا عليك. مثل بقية الادوية التى تستخدم لخفض ضغط الدم, ڤاليستا قد يسبب فى بعض الحالات النادرة دوخة ويؤثر على القدرة على التركيز .</p><p><strong>معلومات ھامة حول بعض مكونات أقراص ڤاليستا</strong></p><p>ھذا الدواء يحتوى على سكر اللاكتوز, إذا أخبرك طبيبك المعالج بعدم استطاعتك لتحمل بعض أنواع السكر, تواصل مع طبيبك المعالج قبل البدء فى تناول ھذا الدواء .</p><p>ڤاليستا يحتوى على زيت الصويا. إذا كنت تعانى من فرط التحسس تجاه الصويا أو الفول السودانى, لاتقم بتناول ھذا الدواء .</p><p>ڤاليستا يحتوى على مادة (110E (FCF الصفراء والتى قد تسبب تفاعلات تحسسية</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائماً بتناول أقراص ڤاليستا بالضبط كما أخبرك طبيبك المعالج للحصول على أفضل النتائج وتقليل خطر الإصابة بالأعراض الجانبية. إذا كنت غير متأكد, يجب أن تتأكد من خلال التواصل مع طبيبك المعالج أو الصيدلى. فى أغلب الأحيان الناس المصابة بارتفاع ضغط الدم لا يقومون بملاحظة أى علامات لهذه المشكلة. فقد يشعر الكثير منهم بأنه طبيعى تماماً. مما يجعل الأمر أكثر أهمية بالنسبة لك للحفاظ على مواعيدك مع الطبيب المعالج حتى لو كنت تشعر بأنك على ما يرام.</p><p><strong>للأطفال والمراهقين (من 6 إلى 18 سنة من العمر) المصابين بارتفاع ضغط الدم</strong></p><p>للمرضى الأقل فى الوزن من 35 كجم تكون الجرعة المعتادة هى 40 ملجم من ڤالسارتان مرة واحدة يومياً.</p><p>للمرضى المتراوحة أوزانهم من 35 كجم فما أكثر تكون عادةً جرعة البداية هى 80 ملجم من ڤالسارتان مرة واحدة يومياً.</p><p>فى بعض الحالات قد يلجأ الطبيب إلى وصف جرعات عالية (يمكن أن تزيد الجرعة إلى 160 ملجم أو بحد أقصى إلى 320 ملجم).</p><p><strong>للمرضى البالغين بعد الإصابة مؤخراً بأزمة قلبية:</strong> بعد الإصابة بأزمة قلبية يبدأ العلاج بشكل عام فى أقرب وقت بعد 12 ساعة, وعادةً بجرعة قليلة 20 ملجم مرتين يومياً. يمكنك الحصول على جرعة 20 ملجم عن طريق قسمة قرص 40 ملجم. سوف يقوم طبيبك المعالج بزيادة هذه الجرعة تدريجياً خلال بضعة أسابيع إلى أن تصل بحد أقصى إلى 160 ملجم مرتين يومياً. سوف تعتمد الجرعة النهائية الخاصة بحالتك على مدى تحملك للعلاج.</p><p>ڤاليستا يمكن تناوله بمصاحبة أدوية أخرى لعلاج النوبة القلبية, وسوف يقرر طبيبك المعالج أى هذه الأدوية هو المناسب لحالتك.</p><p><strong>المرضى البالغين المصابين بفشل القلب:</strong> بشكل عام تكون جرعة البداية هى 40 ملجم مرتين يومياً. سوف يقوم طبيبك المعالج بزيادة هذه الجرعة تدريجياً خلال بضعة أسابيع إلى أن تصل بحد أقصى إلى 160 ملجم مرتين يومياً. سوف تعتمد الجرعة النهائية الخاصة بحالتك على مدى تحملك للعلاج.</p><p>ڤاليستا يمكن تناوله بمصاحبة أدوية أخرى لعلاج فشل القلب, وسوف يقرر طبيبك المعالج أى هذه الأدوية هو المناسب لحالتك.</p><p><strong>المرضى البالغين المصابين بارتفاع ضغط الدم</strong>: تكون الجرعة المعتادة هى 80 ملجم يومياً. فى بعض الحالات قد يصف الطبيب المعالج جرعات عالية (مثلاً 160 ملجم أو 320 ملجم). وقد يلجأ الطبيب أيضاً إلى وصف ڤاليستا مع أدوية إضافية (مثل مدرات البول).</p><p><strong>فى حالة تناولك لأقراص ڤاليستا أكثر مما ينبغى</strong></p><p>إذا تعرضت لدوار شديد و/أو إغماء, استلقِ أفقياً واتصل بطبيبك المعالج فوراً. إذا تناولت خطأ العديد من الأقراص, اتصل بالطبيب أو الصيدلى أو المستشفى فى الحال.</p><p><strong>فى حالة نسيان تناول أقراص ڤاليستا</strong></p><p>لا تقم بتناول جرعة مضاعفة لتعويض الجرعة المفقودة.</p><p>فى حالة نسيان تناول الجرعة, قم بتناولها بمجرد أن تتذكر. إلا إذا كان هذا الوقت تقريباً هو وقت الجرعة التالية, فى هذه الحالة تخطى الجرعة المفقودة.</p><p><strong>فى حالة التوقف عن تناول أقراص ڤاليستا</strong></p><p>توقفك عن تناول أقراص ڤاليستا قد يؤدى إلى تدهور حالتك. لا تتوقف عن تناول العلاج الخاص بك ما لم يخبرك طبيبك المعالج بذلك.</p><p>إذا كانت لديك أى أسئلة إضافية بشأن استخدام هذا الدواء, إسأل طبيبك المعالج أو الصيدلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية, ڤاليستا قد يسبب آثار جانبية, وإن لم تكن تحدث لكل من يتناول هذا الدواء.</p><p>هذه الأعراض الجانبية قد تحدث بمعدلات معينة يمكن تعريفها كالآتى:</p><p>&middot; شائعة جداً: والتى تصيب أكثر من 1 لكل 10 مستخدمين لهذا الدواء.</p><p>&middot; شائعة: والتى تصيب من 1 إلى 10 لكل 100 مستخدم لهذا الدواء.</p><p>&middot; غير شائعة: والتى تصيب من 1 إلى 10 لكل 1000 مستخدم لهذا الدواء.</p><p>&middot; نادرة: والتى تصيب من 1 إلى 10 لكل 10,000 مستخدم لهذا الدواء.</p><p>&middot; نادرة جداً: والتى تصيب أقل من 1 لكل 10,000 مستخدم لهذا الدواء.</p><p>&middot; غير معلومة: والتى لا يمكن تقدير معدل تكرار حدوثها من خلال البيانات المتاحة.</p><p><strong>بعض الأعراض التى تتطلب عناية طبية عاجلة:</strong></p><p>قد تتعرض للإصابة بأعراض الوذمة الوعائية (وهو رد فعل تحسسى خاص), مثل:</p><p>&middot; تورم الوجه أو الشفتين أو اللسان أو الحلق.</p><p>&middot; صعوبة فى التنفس أو البلع.</p><p>&middot; الشرى أو حكة الجلد.</p><p><strong>إذا تعرضت لأى من هذه الأعراض المذكورة أعلاه, تواصل مع طبيبك المعالج فوراً.</strong></p><p>&nbsp;</p><p><strong>أعراض جانبية أخرى وتشمل:</strong></p><p>&nbsp;</p><p><strong>أعراض جانبية شائعة:</strong></p><p>&middot; دوخة</p><p>&middot; انخفاض ضغط الدم مع أو بدون بعض الأعراض مثل الدوخة والإغماء عند الوقوف.</p><p>&middot; انخفاض وظائف الكلى (علامات الخلل الكلوى).</p><p><strong>أعراض جانبية غير شائعة:</strong></p><p>&middot; الوذمة الوعائية (انظر فقرة &quot; بعض الأعراض التى تتطلب عناية طبية عاجلة&quot;)</p><p>&middot; فقدان مفاجئ للوعى (إغماء).</p><p>&middot; إحساس بالدوار</p><p>&middot; نقص حاد فى وظائف الكلى (علامات الفشل الكلوى الحاد)</p><p>&middot; تقلص العضلات وعدم انتظام إيقاع القلب (علامات ارتفاع مستوى البوتاسيوم بالدم)</p><p>&middot; ضيق التنفس أو صعوبة في التنفس عند الاستلقاء وتورم في القدمين أو الساقين (علامات فشل القلب)</p><p>&middot; صداع</p><p>&middot; سعال</p><p>&middot; ألم بالبطن</p><p>&middot; غثيان</p><p>&middot; إسهال</p><p>&middot; إرهاق</p><p>&middot; ضعف</p><p><strong>أعراض جانبية غير معلومة:</strong></p><p>&middot; تفاعلات تحسسية مصحوبة بطفح جلدى وحكة وشرى, أعراض الحمى, تورم وألم بالمفاصل, ألم بالعضلات, تورم الغدد الليمفاوية و/ أو أعراض شبية بالأنفلونزا (علامات لمرض الدم)</p><p>&middot; بقع ذات لون أحمر أرجواني وحمى وحكة (علامات التهاب الأوعية الدموية).</p><p>&middot; نزيف غير معتاد أو كدمات (علامات نقص الصفيحات الدموية)</p><p>&middot; ألم بالعضلات</p><p>&middot; حمى والتهاب في الحلق أو قرح فى الفم بسبب العدوى (أعراض انخفاض مستوى خلايا الدم البيضاء وتسمى أيضا نقص العدلات)</p><p>&middot; انخفاض مستوى الهيموجلوبين وانخفاض نسبة خلايا الدم الحمراء في الدم (والذي قد يؤدي إلى فقر الدم في الحالات الشديدة)</p><p>&middot; ارتفاع مستوى البوتاسيوم بالدم (والذى يزيد من تقلصات العضلات وعدم انتظام إيقاع القلب فى الحالات الشديدة)</p><p>&middot; ارتفاع قيم وظائف الكبد (والتي يمكن أن تشير إلى تلف الكبد) بما في ذلك زيادة البيليروبين في الدم (والتي يمكن أن تسبب اصفرار العين والجلد في الحالات الشديدة)</p><p>&middot; زيادة مستوى اليوريا نيتروجين فى الدم وارتفاع مستوى الكرياتينين بالدم (والذى قد يشير إلى خلل فى وظائف الكلى)</p><p>&middot; انخفاض مستوى الصوديوم فى الدم (والذى قد يزيد من الإرهاق و الارتباك وارتعاش العضلات و / أو التشنجات في الحالات الشديدة)</p><p>معدل تكرار حدوث بعض الأعراض الجانبية قد يختلف اعتماداً على حالتك. على سبيل المثال أعراض جانبية مثل الدوخة وانخفاض وظائف الكلى قد تمت ملاحظتها بمعدل أقل فى حالة المرضى البالغين المعالجين من ارتفاع ضغط الدم منها فى المرضى البالغين المعالجين من فشل القلب أو بعد الإصابة مؤخراً بالأزمة القلبية.</p><p>الأعراض الجانبية فى الأطفال والمراهقين شبيهة بتلك التى تحدث فى حالة البالغين.</p><p><strong>إذا أصبحت أى من هذه الأعراض الجانبية جسيمة أو إذا تعرضت لأى أعراض جانبية أخرى لم يتم ذكرها فى هذه النشرة, فضلاّ أخبر طبيبك المعالج أو الصيدلى بشأنها.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&middot; لا تحفظ فى درجة حرارة أعلى من 30 درجة مئوية. تحفظ فى العبوة الأصلية لحمايتها من الضوء والرطوبة.</p><p>&middot; هذا الدواء لا يتطلب أى ظروف خاصة للتخزين.</p><p>&middot; يحفظ هذا الدواء بعيداً عن متناول ونظر الأطفال.</p><p>&middot; لا تستخدم أقراص ڤاليستا بعد انتهاء تاريخ الصلاحية المدون على العبوة والشريط والزجاجة بعد EXP, علماً بأن تاريخ الصلاحية يشير إلى آخر يوم من الشهر المدون على العلبة.</p><p>&middot; لا يجب التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة ھى: ڤالسارتان</p><p>كل قرص مغطى بطبقة رقيقة يحتوى على 40 ملجم من ڤالسارتان</p><p>. كل قرص مغطى بطبقة رقيقة يحتوى على 80 ملجم من ڤالسارتان .</p><p>كل قرص مغطى بطبقة رقيقة يحتوى على 160 ملجم من ڤالسارتان</p><p>كل قرص مغطى بطبقة رقيقة يحتوى على 320 ملجم من ڤالسارتان .</p><p>&bull; مكونات أخرى وھى :</p><p>لب القرص: لاكتوز مونوھيدرات, ميكروكريستالين سيليولوز, كروسكارميللوز صوديوم, بوفيدون 32K29-K, تالك, ليسيثين (يحتوى على زيت الصويا) (322E) , ثانى أكسيد التيتانيوم (171E) , ( أكسيد الحديد الاصفر )(172E)</p><p>أكسيد الحديد الاصفر (172E ),&nbsp; أكسيد الحديد الاحمر (172E) &nbsp;{فقط لكل من ڤاليستا 80 ملجم و ڤاليستا 160 ملجم }</p><p>أكسيد الحديد الاسود (172E , ( FCF ألومنيوم أصفر لامع (110E ) {&nbsp;فقط فى ڤاليستا 320 ملجم }</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ڤاليستا 40 ملجم أقراص مغطاة بطبقة رقيقة: أقراص صفراء اللون بيضاوية ثنائية التحدب مغطاة بطبقة رقيقة مقاس 4.5x 9 ملليمتر بھا خط للقسمة من أحد الجوانب وعلامة &quot;V &quot;على الجانب الاخر .</p><p>ڤاليستا 80 ملجم أقراص مغطاة بطبقة رقيقة: أقراص وردية اللون دائرية ثنائية التحدب مغطاة بطبقة رقيقة قطرھا 8 ملليمتر بھا خط للقسمة من أحد الجوانب وعلامة &quot;V &quot;على الجانب الاخر .</p><p>ڤاليستا 160 ملجم أقراص مغطاة بطبقة رقيقة: أقراص صفراء اللون بيضاوية ثنائية التحدب مغطاة بطبقة رقيقة مقاس 6.5x 15 ملليمتر بھا خط للقسمة من أحد الجوانب وعلامة &quot;V &quot;على الجانب الاخر .</p><p>ڤاليستا 320 ملجم أقراص مغطاة بطبقة رقيقة: أقراص بنية اللون بيضاوية ثنائية التحدب مغطاة بطبقة رقيقة مقاس 8.2&nbsp; 19x&nbsp;&nbsp;ملليمتر بھا خط للقسمة من أحد الجوانب وعلامة &quot;V &quot;على الجانب الاخر .</p><p>مقاسات العبوة :</p><p>شرائط الومنيوم OPA/AL/PVC و PVC/PE/PVDC</p><p>كل عبوة تحتوى على 7 أو 14 أو 28 أو 56 أو 98 أو 280 قرص .</p><p>قد لا&nbsp;يتم تسويق جميع أحجام العبوات</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إنتاج:</p><p>الدوائية</p><p>مصنع الأدوية بالقصيم</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية.</p><p>المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Valista 40 mg film-coated tablets 
Valista 80 mg film-coated tablets 
Valista 160 mg film-coated tablets 
Valista 320 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One film-coated tablet contains 40 mg of valsartan 
One film-coated tablet contains 80 mg of valsartan 
One film-coated tablet contains 160 mg of valsartan
One film-coated tablet contains 320 mg valsartan. 
Excipients: 
Each Valista 40 mg film-coated tablet contains 21.11 mg lactose monohydrate and 0.126 mg lecithin 
(contains soya oil). 
Each Valista 80 mg film-coated tablet contains 42.22 mg lactose monohydrate and 0.252 mg lecithin 
(contains soya oil) 
Each Valista 160 mg film-coated tablet contains 84.44 mg lactose monohydrate and 0.504 mg lecithin 
(contains soya oil) 
Each Valista 320 mg film-coated tablet contains 168.88 mg lactose monohydrate and 1.01 mg lecithin 
(contains soya oil) and 0.95 mg sunset yellow FCF (E110). 
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet 
Valista 40 mg tablets: Yellow, oval, biconvex, film-coated tablets, 9 x 4.5 mm, with a scoreline on one 
side and marked with a "V" on the other. 
Valista 80 mg tablets: Pink, round, biconvex, film-coated tablets, 8 mm in diameter, with a scoreline on 
both sides and marked with a "V" on one side. 
Valista 160 mg tablets: Yellow, oval, biconvex, film-coated tablets, 15 x 6.5 mm, with a scoreline on one 
side and marked with a "V" on the other. 
Valista 320 mg tablets: Brown, oval, biconvex, film-coated tablets, 19 x 8.2 mm, with a scoreline on one 
side and sidescores and marked with a "V" on the other. 
The tablet can be divided into equal halves.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypertension</u></p><p>Treatment of hypertension in children and adolescents 6 to 18 years of age.</p><p><u>Recent myocardial infarction </u></p><p>Treatment of clinically stable adult patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 hours -to 10 days) myocardial infarction (see sections 4.4 and 5.1).</p><p><u>Heart failure</u></p><p>Treatment of symptomatic heart failure in adult patients when Angiotensin Converting Enzyme (ACE) inhibitors cannot be used, or as add-on therapy to ACE inhibitors when beta blockers cannot be used (see sections 4.4 and 5.1).</p><p><u>Hypertension</u></p><p>Treatment of essential hypertension in adults, and hypertension in children and adolescents 6 to 18 years of age.</p><p><u>Recent myocardial infarction </u></p><p>Treatment of clinically stable adult patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 hours to 10 days) myocardial infarction (see sections 4.4 and 5.1).</p><p><u>Heart failure</u></p><p>Treatment of symptomatic heart failure in adult patients when Angiotensin Converting Enzyme (ACE) inhibitors cannot be used, or as add-on therapy to ACE inhibitors when beta blockers cannot be used (see sections 4.4 and 5.1).</p><p><u>Hypertension</u></p><p>Treatment of essential hypertension in adults, and hypertension in children and adolescents 6 to 18 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology </u></p><p><u>Recent myocardial infarctio</u>n</p><p>In clinically stable patients, therapy may be initiated as early as 12 hours after a myocardial infarction. After an initial dose of 20 mg twice daily, valsartan should be titrated to 40 mg, 80 mg, and 160 mg twice daily over the next few weeks. The starting dose is provided by the 40 mg divisible tablet. The target maximum dose is 160 mg twice daily. In general, it is recommended that patients achieve a dose level of 80 mg twice daily by two weeks after treatment initiation and that the target maximum dose, 160 mg twice daily, be achieved by three months, based on the patient&#39;s tolerability. If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dose reduction. Valsartan may be used in patients treated with other post-myocardial infarction therapies, e.g. thrombolytics, acetylsalicylic acid, beta blockers, statins, and diuretics. The combination with ACE inhibitors is not recommended (see sections 4.4 and 5.1). Evaluation of post-myocardial infarction patients should always include assessment of renal function.</p><p><u>Heart failure</u></p><p>&nbsp;The recommended starting dose of Valista is 40 mg twice daily. Uptitration to 80 mg and 160 mg twice daily should be done at intervals of at least two weeks to the highest dose, as tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320 mg in divided doses. Valsartan may be administered with other heart failure therapies. However, the triple combination of an ACE inhibitor, a beta blocker and valsartan is not recommended (see sections 4.4 and 5.1). Evaluation of patients with heart failure should always include assessment of renal function.</p><p><u>Hypertension</u></p><p>The recommended starting dose of Valista is 80 mg once daily. The antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 160 mg and to a maximum of 320 mg. Valista may also be administered with other antihypertensive agents. The addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients.</p><p><u>Recent myocardial infarction</u></p><p>In clinically stable patients, therapy may be initiated as early as 12 hours after a myocardial infarction. After an initial dose of 20 mg twice daily, valsartan should be titrated to 40 mg, 80 mg, and 160 mg twice daily over the next few weeks. The starting dose is provided by the 40 mg divisible tablet. The target maximum dose is 160 mg twice daily. In general, it is recommended that patients achieve a dose level of 80 mg twice daily by two weeks after treatment initiation and that the target maximum dose, 160 mg twice daily, be achieved by three months, based on the patient&#39;s tolerability. If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dose reduction. Valsartan may be used in patients treated with other post-myocardial infarction therapies, e.g. thrombolytics, acetylsalicylic acid, beta blockers, statins, and diuretics. The combination with ACE inhibitors is not recommended (see sections 4.4 and 5.1). Evaluation of post-myocardial infarction patients should always include assessment of renal function.</p><p><u>Heart failure</u></p><p>The recommended starting dose of Valista is 40 mg twice daily. Uptitration to 80 mg and 160 mg twice daily should be done at intervals of at least two weeks to the highest dose, as tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320 mg in divided doses. Valsartan may be administered with other heart failure therapies. However, the triple combination of an ACE inhibitor, a beta blocker and valsartan is not recommended (see sections 4.4 and 5.1). Evaluation of patients with heart failure should always include assessment of renal function.</p><p><u>Hypertension</u></p><p>The recommended starting dose of Valista is 80 mg once daily. The antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 160 mg and to a maximum of 320 mg. Valista may also be administered with other antihypertensive agents. The addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients.</p><p><u>Additional information on special populations</u></p><p><u>Elderly</u></p><p>No dose adjustment is required in elderly patients.&nbsp;</p><p><u>Renal impairment</u></p><p>No dose adjustment is required for adult patients with a creatinine clearance &gt;10 ml/min (see sections 4.4 and 5.2)</p><p><u>Hepatic impairment</u></p><p>&nbsp;Valista is contraindicated in patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). In patients with mild to moderate hepatic impairment without cholestasis, the dose of valsartan should not exceed 80 mg.</p><p><u>Paediatric population</u></p><p><u>Paediatric hypertension</u></p><p>Children and adolescents 6 to 18 years of age</p><p>The initial dose is 40 mg once daily for children weighing below 35 kg and 80 mg once daily for those weighing 35 kg or more. The dose should be adjusted based on blood pressure response. For maximum doses studied in clinical trials please refer to the table below.</p><p>Doses higher than those listed have not been studied and are therefore not recommended.</p><p>&nbsp; &nbsp; &nbsp; Weight&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Maximum dose studied in clinical trials&nbsp;</p><p>&nbsp; &nbsp;&nbsp; &ge;18 kg to &lt;35 kg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;80 mg</p><p>&nbsp; &nbsp; &nbsp;&ge;35 kg to &lt;80 kg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 160 mg</p><p>&nbsp; &nbsp; &ge;80 kg to &le;160 kg&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;320 mg&nbsp;</p><p>&nbsp;</p><p><em>Children less than 6 years of age</em></p><p>Available data are described in sections 4.8, 5.1 and 5.2. However safety and efficacy of valsartan in children aged 1 to 6 years have not been established.</p><p><u>Use in paediatric patients aged 6 to 18 years with renal impairment</u></p><p>Use in paediatric patients with a creatinine clearance 30 ml/min. Renal function and serum potassium should be closely monitored (see sections 4.4 and 5.2).</p><p><u>Use in paediatric patients aged 6 to 18 years with hepatic impairment</u></p><p>As in adults, Valista is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). There is limited clinical experience with valsartan in paediatric patients with mild to moderate hepatic impairment. The dose of valsartan should not exceed 80 mg in these patients.</p><p><u>Paediatric heart failure and recent myocardial infarction</u></p><p>Valsartan is not recommended for the treatment of heart failure or recent myocardial infarction in children and adolescents below the age of 18 years due to the lack of data on safety and efficacy.</p><p><u>Method of administration</u></p><p>Valista may be taken independently of a meal and should be administered with water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -Hypersensitivity to the active substance, soya oil, peanut oil or to any of the excipients (see section 6.1). 
-Severe hepatic impairment, biliary cirrhosis and cholestasis. 
-Second and third trimester of pregnancy (see sections 4.4 and 4.6
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hyperkalaemia</u></p><p>Concomitant use with potassium supplements, potassium -sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.</p><p><u>Sodium- and/or volume -depleted patients</u></p><p>In severely sodium-depleted and/or volume -depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with valsartan. Sodium and/or volume depletion should be corrected before starting treatment with Valista, for example by reducing the diuretic dose.</p><p><u>Renal artery stenosis </u></p><p>In patients with bilateral renal artery stenosis or stenosis to a solitary kidney, the safe use of valsartan has not been established. Short-term administration of valsartan to twelve patients with renovascular hypertension secondary to unilateral renal artery stenosis did not induce any significant changes in renal haemodynamics, serum creatinine, or blood urea nitrogen (BUN). However, other agents that affect the renin-angiotensin system may increase blood urea and serum creatinine in patients with unilateral renal artery stenosis, therefore monitoring of renal function is recommended when patients are treated with valsartan.</p><p><u>Kidney transplantation</u></p><p>There is currently no experience on the safe use of valsartan in patients who have recently undergone kidney transplantation.</p><p><u>Primary hyperaldosteronism</u></p><p>Patients with primary hyperaldosteronism should not be treated with valsartan as their renin-angiotensin system is not activated.</p><p><u>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</u></p><p>As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).</p><p><u>Impaired renal function</u></p><p>There is currently no experience on the safe use in patients with a creatinine clearance 10 ml/min (see sections 4.2 and 5.2).</p><p><u>Hepatic impairment</u></p><p>In patients with mild to moderate hepatic impairment without cholestasis, valsartan should be used with caution (see sections 4.2 and 5.2).</p><p><u>Pregnancy</u></p><p>Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti -hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).&nbsp;</p><p><u>Recent myocardial infarction </u></p><p>The combination of captopril and valsartan has shown no additional clinical benefit, instead the risk for adverse events increased compared to treatment with the respective therapies (see sections 4.2 and 5.1). Therefore, the combination of valsartan with an ACE inhibitor is not recommended. Caution should be observed when initiating therapy in post -myocardial infarction patients. Evaluation of post -myocardial infarction patients should always include assessment of renal function (see section 4.2). Use of valsartan in post -myocardial infarction patients commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2).</p><p>Heart Failure</p><p>In patients with heart failure, the triple combination of an ACE inhibitor, a beta blocker and valsartan has not shown any clinical benefit (see section 5.1). This combination apparently increases the risk for adverse events and is therefore not recommended. Caution should be observed when initiating therapy in patients with heart failure. Evaluation of patients with heart failure should always include assessment of renal function (see section 4.2). Use of valsartan in patients with heart failure commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2). In patients whose renal function may depend on the activity of the renin -angiotensin system (e.g patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia and in rare cases with acute renal failure and/or death. As valsartan is an angiotensin II antagonist, it cannot be excluded that the use of valsartan may be associated with impairment of the renal function.</p><p>Recent myocardial infarction</p><p>The combination of captopril and valsartan has shown no additional clinical benefit, instead the risk for adverse events increased compared to treatment with the respective therapies (see sections 4.2 and 5.1). Therefore, the combination of valsartan with an ACE inhibitor is not recommended. Caution should be observed when initiating therapy in post -myocardial infarction patients. Evaluation of post-myocardial infarction patients should always include assessment of renal function (see section 4.2). Use of valsartan in post -myocardial infarction patients commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2). Heart Failure In patients with heart failure, the triple combination of an ACE inhibitor, a beta blocker and valsartan has not shown any clinical benefit (see section 5.1). This combination apparently increases the risk for adverse events and is therefore not recommended. Caution should be observed when initiating therapy in patients with heart failure. Evaluation of patients with heart failure should always include assessment of renal function (see section 4.2). Use of valsartan in patients with heart failure commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2). In patients whose renal function may depend on the activity of the renin -angiotensin system (e.g patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia and in rare cases with acute renal failure and/or death. As valsartan is an angiotensin II antagonist, it cannot be excluded that the use of valsartan may be associated with impairment of the renal function. S Other conditions with stimulation of the renin-angiotensin system In patients whose renal function may depend on the activity of the rennin-angiotensin system (e.g patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia and in rare cases with acute renal failure and/or death. As valsartan is an angiotensin II antagonist, it cannot be excluded that the use of valsartan may be associated with impairment of the renal function. Paediatric population Impaired renal function Use in paediatric patients with a creatinine clearance 30 ml/min (see sections 4.2 and 5.2). Renal function and serum potassium should be closely monitored during treatment with valsartan. This applies particularly when valsartan is given in the presence of other conditions (fever, dehydration) likely to impair renal function. Impaired hepatic function As in adults, Valista is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3 and 5.2). There is limited clinical experience with valsartan in paediatric patients with mild to moderate hepatic impairment. The dose of valsartan should not exceed 80 mg in these patients. Galactose intolerance, Lapp lactase deficiency, glucose -galactose malabsorbtion Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Lecithin If a patient is hypersensitive to peanut or soya, this medicine should not be used. Sunset yellow FCF (E110) Valista 320 mg film-coated tablets contain Sunset yellow FCF (E110) which may cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Concomitant use not recommended</u></p><p><em>Lithium</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors. Due to the lack of experience with concomitant use of valsartan and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><em>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</em></p><p>If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised.</p><p><u>Caution required with concomitant use</u></p><p><em>Non-steroidal anti-inflammatory medicines (NSAIDs),</em> including selective COX-2 inhibitors, acetylsalicylic acid &gt;3 g/day), and non-selective NSAIDs When angiotensin II antagonists are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</p><p><u>Others</u></p><p>In drug interaction studies with valsartan, no interactions of clinical significance have been found with valsartan or any of the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide.</p><p><u>Paediatric population</u></p><p>In hypertension in children and adolescents, where underlying renal abnormalities are common, caution is recommended with the concomitant use of valsartan and other substances that inhibit the renin angiotensin aldosterone system which may increase serum potassium. Renal function and serum potassium should be closely monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4)</td></tr></tbody></table><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started. AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalemia); see also section 5.3 &ldquo;Preclinical safety data&rdquo;. Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p><u>Lactation</u></p><p>Because no information is available regarding the use of valsartan during breastfeeding, Valista is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><u>Fertility</u></p><p>Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive have been performed. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In controlled clinical studies in adult patients with hypertension, the overall incidence of adverse reactions (ADRs) was comparable with placebo and is consistent with the pharmacology of valsartan. The incidence of ADRs did not appear to be related to dose or treatment duration and also showed no association with gender, age or race.</p><p>The ADRs reported from clinical studies, post-marketing experience and laboratory findings are listed below according to system organ class.</p><p>Adverse reactions are ranked by frequency, the most frequent first, using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000) very rare (&lt; 1/10,000), including isolated reports. Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness. For all the ADRs reported from post-marketing experience and laboratory findings, it is not possible to apply any ADR frequency and therefore they are mentioned with a &quot;not known&quot; frequency.</p><p><strong>&nbsp;</strong></p><ul><li>&nbsp;<strong>&nbsp;&nbsp; Hypertension</strong></li></ul><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Decrease in haemoglobin, decrease in haematocrit, neutropenia, thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity including serum sickness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase of serum potassium, hyponatremia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepato‑biliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Elevation of liver function values including increase of serum bilirubin</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Angioedema, rash, pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure and impairment, elevation of serum creatinine</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Paediatric population </u></p><p><u>Hypertension</u></p><p>The antihypertensive effect of valsartan has been evaluated in two randomised, double-blind clinical studies in 561 paediatric patients from 6 to 18 years of age. With the exception of isolated gastrointestinal disorders (like abdominal pain, nausea, vomiting) and dizziness, no relevant differences in terms of type, frequency and severity of adverse reactions were identified between the safety profile for paediatric patients aged 6 to 18 years and that previously reported for adult patients.</p><p>Neurocognitive and developmental assessment of paediatric patients aged 6 to 16 years of age revealed no overall clinically relevant adverse impact after treatment with valsartan for up to one year.</p><p>In a double-blind randomized study in 90 children aged 1 to 6 years, which was followed by a one-year open-label extension, two deaths and isolated cases of marked liver transaminases elevations were observed. These cases occurred in a population who had significant comorbidities. A causal relationship to valsartan has not been established. In a second study in which 75 children aged 1 to 6 years were randomised, no significant liver transaminase elevations or death occurred with valsartan treatment.</p><p>Hyperkalaemia was more frequently observed in children and adolescents aged 6 to 18 years with underlying chronic kidney disease.</p><p>The safety profile seen in controlled-clinical studies in adult patients with post-myocardial infarction and/or heart failure varies from the overall safety profile seen in hypertensive patients. This may relate to the patients underlying disease. ADRs that occurred in post-myocardial infarction and/or heart failure patients are listed below:&middot;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><ul><li><strong>&nbsp;&nbsp; Post‑myocardial infarction and/or heart failure</strong></li></ul><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity including serum sickness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hyperkalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase of serum potassium, hyponatremia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness, postural dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Syncope, headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cardiac failure</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension, orthostatic hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nausea, diarrhoea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepato‑biliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Elevation of liver function values</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Rash, pruritis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Renal failure and impairment</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Acute renal failure, elevation of serum creatinine</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase in Blood Urea Nitrogen</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Asthenia, fatigue</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Overdose with Valista may result in marked hypotension, which could lead to depressed level of consciousness, circulatory collapse and/or shock.</p><p><u>Treatment</u></p><p>The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms; stabilisation of the circulatory condition is of prime importance.</p><p>If hypotension occurs, the patient should be placed in a supine position and blood volume correction should be undertaken.</p><p>Valsartan is unlikely to be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II Antagonists, plain, ATC code: C09CA03</p><p>Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. The increased plasma levels of Ang II following AT1 receptor blockade with valsartan may stimulate the unblocked AT2 receptor, which appears to counterbalance the effect of the AT1 receptor. Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000 fold) greater affinity for the AT1 receptor than for the AT2 receptor. Valsartan is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular&nbsp;regulation. Valsartan does not inhibit ACE (also known as kininase II) which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (P&lt;0.05) less in patients treated with valsartan than in those treated with an ACE inhibitor (2.6 % versus 7.9 % respectively). In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5 % of trial subjects receiving valsartan and 19.0 % of those receiving a thiazide diuretic experienced cough compared to 68.5 % of those treated with an ACE inhibitor (P &lt; 0.05).</p><p>&nbsp;</p><p><u>Recent myocardial infarction</u></p><p>The VALsartan In Acute myocardial iNfarcTion trial (VALIANT) was a randomised, controlled, multinational, double-blind study in 14,703 patients with acute myocardial infarction and signs, symptoms or radiological evidence of congestive heart failure and/or evidence of left ventricular systolic dysfunction (manifested as an ejection fraction &le; 40 % by radionuclide ventriculography or &le; 35 % by echocardiography or ventricular contrast angiography). Patients were randomised within 12 hours to 10 days after the onset of myocardial infarction symptoms to valsartan, captopril, or the combination of both. The mean treatment duration was two years. The primary endpoint was time to all-cause mortality. Valsartan was as effective as captopril in reducing all-cause mortality after myocardial infarction. All-cause mortality was similar in the valsartan (19.9 %), captopril (19.5 %), and valsartan + captopril (19.3 %) groups. Combining valsartan with captopril did not add further benefit over captopril alone. There was no difference between valsartan and captopril in all-cause mortality based on age, gender, race, baseline therapies or underlying disease. Valsartan was also effective in prolonging the time to and reducing cardiovascular mortality, hospitalisation for heart failure, recurrent myocardial infarction, resuscitated cardiac arrest, and non-fatal stroke (secondary composite endpoint). The safety profile of valsartan was consistent with the clinical course of patients treated in the post-myocardial infarction setting. Regarding renal function, doubling of serum creatinine was observed in 4.2 % of valsartan-treated patients, 4.8 % of valsartan+captopril-treated patients, and 3.4 % of captopril-treated patients. Discontinuations due to various types of renal dysfunction occurred in 1.1 % of valsartan-treated patients, 1.3 % in valsartan+captopril patients, and 0.8 % of captopril patients. An assessment of renal function should be included in the evaluation of patients post-myocardial infarction. There was no difference in all-cause mortality, cardiovascular mortality or morbidity when beta blockers were administered together with the combination of valsartan + captopril, valsartan alone, or captopril alone. Irrespective of treatment, mortality was lower in the group of patients treated with a beta blocker, suggesting that the known beta blocker benefit in this population was maintained in this trial.</p><p>&nbsp;</p><p><u>Heart failure</u></p><p>Val-HeFT was a randomised, controlled, multinational clinical trial of valsartan compared with placebo on morbidity and mortality in 5,010 NYHA class II (62 %), III (36 %) and IV (2 %) heart failure patients receiving usual therapy with LVEF 2.9 cm/m2. Baseline therapy included ACE inhibitors (93 %), diuretics (86 %), digoxin (67 %) and beta blockers (36 %). The mean duration of follow-up was nearly two years. The mean daily dose of valsartan in Val-HeFT was 254 mg. The study had two primary endpoints: all cause mortality (time to death) and composite mortality and heart failure morbidity (time to first morbid event) defined as death, sudden death with resuscitation, hospitalisation for heart failure, or administration of intravenous inotropic or vasodilator agents for four hours or more without hospitalisation. All cause mortality was similar (p=NS) in the valsartan (19.7 %) and placebo (19.4 %) groups. The primary benefit was a 27.5 % (95 % CI: 17 to 37 %) reduction in risk for time to first heart failure hospitalisation (13.9 % vs. 18.5 %). Results appearing to favour placebo (composite mortality and morbidity was 21.9 % in placebo vs. 25.4 % in valsartan group) were observed for those patients receiving the triple combination of an ACE inhibitor, a beta blocker and valsartan.</p><p>In a subgroup of patients not receiving an ACE inhibitor (n=366), the morbidity benefits were greatest. In this subgroup all-cause mortality was significantly reduced with valsartan compared to placebo by 33 % (95 % CI: &ndash;6 % to 58 %) (17.3 % valsartan vs. 27.1 % placebo) and the composite mortality and morbidity risk was significantly reduced by 44 % (24.9 % valsartan vs. 42.5 % placebo). In patients receiving an ACE inhibitor without a beta-blocker, all cause mortality was similar (p=NS) in the valsartan (21.8 %) and placebo (22.5 %) groups. Composite mortality and morbidity risk was significantly reduced by 18.3 % (95 % CI: 8 % to 28 %) with valsartan compared with placebo (31.0 % vs. 36.3 %). In the overall Val-HeFT population, valsartan treated patients showed significant improvement in NYHA class, and heart failure signs and symptoms, including dyspnoea, fatigue, oedema and rales compared to placebo. Patients treated with valsartan had a better quality of life as demonstrated by change in the Minnesota Living with Heart Failure Quality of Life score from baseline at endpoint than placebo. Ejection fraction in valsartan treated patients was significantly increased and LVIDD significantly reduced from baseline at endpoint compared to placebo.</p><p><u>Hypertension</u></p><p>Administration of valsartan to patients with hypertension results in reduction of blood pressure without affecting pulse rate. In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after dosing. During repeated dosing, the antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks and persist during long-term therapy. Combined with hydrochlorothiazide, a significant additional reduction in blood pressure is achieved. Abrupt withdrawal of valsartan has not been associated with rebound hypertension or other adverse clinical events. In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80-160 mg/od) versus amlodipine (5-10 mg/od), in 332 type 2 diabetic patients (mean age: 58 years; 265 men) with microalbuminuria (valsartan: 58 &micro;g/min; amlodipine: 55.4 &micro;g/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120 &micro;mol/l). At 24 weeks, UAE was reduced (p&lt;0.001) by 42 % (&ndash;24.2 &micro;g/min; 95 % CI: &ndash;40.4 to &ndash;19.1) with valsartan and approximately 3 % (&ndash;1.7 &micro;g/min; 95 % CI: &ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups. The valsartan Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/88 mmHg) with type 2 diabetes, albuminuria (mean=102 &micro;g/min; 20-700 &micro;g/min) and preserved renal function (mean serum creatinine = 80 &micro;mol/l). Patients were randomized to one of 3 doses of valsartan (160, 320 and 640 mg/od) and treated for 30 weeks. The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage change in UAE was significantly reduced by 36 % from baseline with valsartan 160 mg (95 %CI: 22 to 47 %), and by 44 % with valsartan 320 mg (95 %CI: 31 to 54 %). It was concluded that 160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.</p><p><u>Recent myocardial infarction</u></p><p>The VALsartan In Acute myocardial iNfarcTion trial (VALIANT) was a randomised, controlled, multinational, double-blind study in 14,703 patients with acute myocardial infarction and signs, symptoms or radiological evidence of congestive heart failure and/or evidence of left ventricular systolic dysfunction (manifested as an ejection fraction &le;40 % by radionuclide ventriculography or &le;35 % by echocardiography or ventricular contrast angiography). Patients were randomised within 12 hours to 10 days after the onset of myocardial infarction symptoms to valsartan, captopril, or the combination of both. The mean treatment duration was two years. The primary endpoint was time to all-cause mortality. Valsartan was as effective as captopril in reducing all-cause mortality after myocardial infarction. All-cause mortality was similar in the valsartan (19.9 %), captopril (19.5 %), and valsartan + captopril (19.3 %) groups. Combining valsartan with captopril did not add further benefit over captopril alone. There was no difference between valsartan and captopril in all-cause mortality based on age, gender, race, baseline therapies or underlying disease. Valsartan was also effective in prolonging the time to and reducing cardiovascular mortality, hospitalisation for heart failure, recurrent myocardial infarction, resuscitated cardiac arrest, and non-fatal stroke (secondary composite endpoint). The safety profile of valsartan was consistent with the clinical course of patients treated in the post-myocardial infarction setting. Regarding renal function, doubling of serum creatinine was observed in 4.2 % of valsartan-treated patients, 4.8 % of valsartan+captopril-treated patients, and 3.4 % of captopril-treated patients. Discontinuations due to various types of renal dysfunction occurred in 1.1 % of valsartan-treated patients, 1.3 % in valsartan+captopril patients, and 0.8 % of captopril patients. An assessment of renal function should be included in the evaluation of patients post-myocardial infarction. There was no difference in all-cause mortality, cardiovascular mortality or morbidity when beta blockers were administered together with the combination of valsartan + captopril, valsartan alone, or captopril alone. Irrespective of treatment, mortality was lower in the group of patients treated with a beta blocker, suggesting that the known beta blocker benefit in this population was maintained in this trial.</p><p><u>Heart failure</u></p><p>Val-HeFT was a randomised, controlled, multinational clinical trial of valsartan compared with placebo on morbidity and mortality in 5,010 NYHA class II (62 %), III (36 %) and IV (2 %) heart failure patients receiving usual therapy with LVEF 2.9 cm/m2. Baseline therapy included ACE inhibitors (93 %), diuretics (86 %), digoxin (67 %) and beta blockers (36 %). The mean duration of follow-up was nearly two years. The mean daily dose of valsartan in Val-HeFT was 254 mg. The study had two primary endpoints: all cause mortality (time to death) and composite mortality and heart failure morbidity (time to first morbid event) defined as death, sudden death with resuscitation, hospitalisation for heart failure, or administration of intravenous inotropic or vasodilator agents for four hours or more without hospitalisation. All cause mortality was similar (p=NS) in the valsartan (19.7 %) and placebo (19.4 %) groups. The primary benefit was a 27.5 % (95 % CI: 17 to 37 %) reduction in risk for time to first heart failure hospitalisation (13.9 % vs. 18.5 %). Results appearing to favour placebo (composite mortality and morbidity was 21.9 % in placebo vs. 25.4 % in valsartan group) were observed for those patients receiving the triple combination of an ACE inhibitor, a beta blocker and valsartan. In a subgroup of patients not receiving an ACE inhibitor (n=366), the morbidity benefits were greatest. In this subgroup all-cause mortality was significantly reduced with valsartan compared to placebo by 33 % (95 % CI: &ndash;6 % to 58 %) (17.3 % valsartan vs. 27.1 % placebo) and the composite mortality and morbidity risk was significantly reduced by 44 % (24.9 % valsartan vs. 42.5 % placebo). In patients receiving an ACE inhibitor without a beta-blocker, all cause mortality was similar (p=NS) in the valsartan (21.8 %) and placebo (22.5 %) groups. Composite mortality and morbidity risk was significantly reduced by 18.3 % (95 % CI: 8 % to 28 %) with valsartan compared with placebo (31.0 % vs. 36.3 %). In the overall Val-HeFT population, valsartan treated patients showed significant improvement in NYHA class, and heart failure signs and symptoms, including dyspnoea, fatigue, oedema and ralescompared to&nbsp;placebo. Patients treated with valsartan had a better quality of life as demonstrated by change in the Minnesota Living with Heart Failure Quality of Life score from baseline at endpoint than placebo. Ejection fraction in valsartan treated patients was significantly increased and LVIDD significantly reduced from baseline at endpoint compared to placebo.</p><p><u>Hypertension</u></p><p>Administration of valsartan to patients with hypertension results in reduction of blood pressure without affecting pulse rate. In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after dosing. During repeated dosing, the antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks and persist during long-term therapy. Combined with hydrochlorothiazide, a significant additional reduction in blood pressure is achieved. Abrupt withdrawal of valsartan has not been associated with rebound hypertension or other adverse clinical events. In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with Valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80-160 mg/od) versus amlodipine (5-10 mg/od), in 332 type 2 diabetic patients (mean age: 58 years; 265 men) with microalbuminuria (valsartan: 58 &micro;g/min; amlodipine: 55.4 &micro;g/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120 &micro;mol/l). At 24 weeks, UAE was reduced (p&lt;0.001) by 42 % (&ndash;24.2 &micro;g/min; 95 % CI: &ndash;40.4 to &ndash;19.1) with valsartan and approximately 3 % (&ndash;1.7 &micro;g/min; 95 % CI: &ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups. The valsartan Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/88 mmHg) with type 2 diabetes, albuminuria (mean=102 &micro;g/min; 20-700 &micro;g/min) and preserved renal function (mean serum creatinine = 80 &micro;mol/l). Patients were randomized to one of 3 doses of valsartan (160, 320 and 640 mg/od) and treated for 30 weeks. The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage change in UAE was significantly reduced by 36 % from baseline with valsartan 160 mg (95 %CI: 22 to 47 %), and by 44 % with valsartan 320 mg (95 %CI: 31 to 54 %). It was concluded that 160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.</p><p><u>Paediatric population </u></p><p><u>Hypertension</u></p><p>The antihypertensive effects of valsartan have been evaluated in four randomized, double-blind clinical studies in 561 paediatric patients from 6 to 18 years of age and 165 paediatric patients 1 to 6 years of age. Renal and urinary disorders, and obesity were the most common underlying medical conditions potentially contributing to hypertension in the children enrolled in these studies. Clinical experience in children at or above 6 years of age In a clinical study involving 261 hypertensive paediatric patients 6 to 16 years of age, patients who weighed &lt;35 kg received 10, 40 or 80 mg of valsartan tablets daily (low, medium and high doses), and patients who weighed &ge;35 kg received 20, 80, and 160 mg of valsartan tablets daily (low, medium and high doses). At the end of 2 weeks, valsartan reduced both systolic and diastolic blood pressure in a dose-dependent manner. Overall, the three dose levels of valsartan (low, medium and high) significantly reduced systolic blood&nbsp;pressure by 8, 10, 12 mm Hg from the baseline, respectively. Patients were re-randomized to either continue receiving the same dose of valsartan or were switched to placebo. In patients who continued to receive the medium and high doses of valsartan, systolic blood pressure at trough was -4 and -7 mm Hg lower than patients who received the placebo treatment. In patients receiving the low dose of valsartan, systolic blood pressure at trough was similar to that of patients who received the placebo treatment. Overall, the dose-dependent antihypertensive effect of valsartan was consistent across all the demographic subgroups. In another clinical study involving 300 hypertensive paediatric patients 6 to 18 years of age, eligible patients were randomized to receive valsartan or enalapril tablets for 12 weeks. Children weighing between &ge;18 kg and &lt;35 kg received valsartan 80 mg or enalapril 10 mg; those between &ge;35 kg and &lt;80 kg received valsartan 160 mg or enalapril 20 mg; those &ge;80 kg received valsartan 320 mg or enalapril 40 mg. Reductions in systolic blood pressure were comparable in patients receiving valsartan (15 mmHg) and enalapril (14 mm Hg) (non-inferiority p-value &lt;0.0001). Consistent results were observed for diastolic blood pressure with reductions of 9.1 mmHg and 8.5 mmHg with valsartan and enalapril, respectively.</p><p>&nbsp;</p><p><u><em>Clinical experience in children less than 6 years of age</em></u></p><p>Two clinical studies were conducted in patients aged 1 to 6 years with 90 and 75 patients, respectively. No children below the age of 1 year were enrolled in these studies. In the first study, the efficacy of valsartan was confirmed compared to placebo but a dose-response could not be demonstrated. In the second study, higher doses of valsartan were associated with greater BP reductions, but the dose response trend did not achieve statistical significance and the treatment difference compared to placebo was not significant. Because of these inconsistencies, valsartan is not recommended in this age group (see section 4.8). The European Medicines Agency has waived the obligation to submit the results of studies with valsartan in all subsets of the paediatric population in heart failure and heart failure after recent myocardial infarction. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong>:</p><p>Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2&ndash;4 hours with tablets and 1-2 hours with solution formulation. Mean absolute bioavailability is 23% and 39% with tablets and solution formulation, respectively. Food decreases exposure (as measured by AUC) to valsartan by about 40 % and peak plasma concentration (Cmax) by about 50 %, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.</p><p><strong>Distribution</strong>:</p><p>The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94&ndash;97 %), mainly serum albumin.</p><p><strong>Biotransformation: </strong></p><p>Valsartan is not biotransformed to a high extent as only about 20 % of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10 % of the valsartan AUC). This metabolite is pharmacologically inactive.</p><p><strong>Excretion</strong>:</p><p>Valsartan shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Valsartan is primarily eliminated by biliary excretion in faeces (about 83 % of dose) and renally in urine (about 13 % of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30 % of total clearance). The half-life of valsartan is 6 hours</p><p>&nbsp;</p><p><strong>In heart failure patients: </strong></p><p>The average time to peak concentration and elimination half-life of valsartan in heart failure patients are similar to that observed in healthy volunteers. AUC and Cmax values of valsartan are almost proportional with increasing dose over the clinical dosing range (40 to 160 mg twice a day). The average accumulation factor is about 1.7. The apparent clearance of valsartan following oral administration is approximately 4.5 l/h. Age does not affect the apparent clearance in heart failure patients.</p><p><strong>In heart failure patients:</strong></p><p>The average time to peak concentration and elimination half-life of valsartan in heart failure patients are similar to that observed in healthy volunteers. AUC and Cmax values of valsartan are almost proportional with increasing dose over the clinical dosing range (40 to 160 mg twice a day). The average accumulation factor is about 1.7. The apparent clearance of valsartan following oral administration is approximately 4.5 l/h. Age does not affect the apparent clearance in heart failure patients.</p><p><strong>Special populations </strong></p><p><strong>Elderly</strong></p><p>A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance.</p><p><strong>Impaired renal function</strong></p><p>As expected for a compound where renal clearance accounts for only 30 % of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan. Dose adjustment is therefore not required in patients with renal impairment (creatinine clearance &gt;10 ml/min). There is currently no experience on the safe use in patients with a creatinine clearance &lt;10 ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients (see sections 4.2 and 4.4). Valsartan is highly bound to plasma protein and is unlikely to be removed by dialysis.</p><p><strong>Hepatic impairment </strong></p><p>Approximately 70 % of the dose absorbed is eliminated in the bile, essentially in the unchanged form. Valsartan does not undergo any noteworthy biotransformation. A doubling of exposure (AUC) was observed in patients with mild to moderate hepatic impairment compared to healthy subjects. However, no correlation was observed between plasma valsartan concentration versus degree of hepatic dysfunction. Valsartan has not been studied in patients with severe hepatic dysfunction (see sections 4.2, 4.3 and 4.4).</p><p><strong>Paediatric population</strong></p><p>In a study of 26 paediatric hypertensive patients (aged 1 to 16 years) given a single dose of a suspension of valsartan (mean: 0.9 to 2 mg/kg, with a maximum dose of 80 mg), the clearance (litres/h/kg) of valsartan was comparable across the age range of 1 to 16 years and similar to that of adults receiving the same formulation.</p><p><strong>Impaired renal function</strong></p><p>Use in paediatric patients with a creatinine clearance 30 ml/min. Renal function and serum potassium should be closely monitored (see sections 4.2 and 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential. In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient). In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient). In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine. Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p><p><u>Paediatric population</u></p><p>Daily oral dosing of neonatal/juvenile rats (from a postnatal day 7 to postnatal day 70) with valsartan at doses as low as 1 mg/kg/day (about 10-35% of the maximum recommended paediatric dose of 4 mg/kg/day on systemic exposure basis) produced persistent, irreversible kidney damage. These effects above mentioned represent an expected exaggerated pharmacological effect of angiotensin converting enzyme inhibitors and angiotensin II type 1 blockers; such effects are observed if rats are treated during the first 13 days of life. This period coincides with 36 weeks of gestation in humans, which could occasionally extend up to 44 weeks after conception in humans. The rats in the juvenile valsartan study were dosed up to day 70, and effects on renal maturation (postnatal 4-6 weeks) cannot be excluded. Functional renal maturation is an ongoing process within the first year of life in humans. Consequently, a clinical relevance in children &lt;1 year of age cannot be excluded, while preclinical data do not indicate a safety concern for children older than 1 year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core</p><p>Lactose monohydrate</p><p>Cellulose, microcrystalline</p><p>Croscarmellose sodium</p><p>Povidone K29-K32</p><p>Talc</p><p>Magnesium Stearate</p><p>Colloidal anhydrous silica</p><p><em>Film-coat</em></p><p>Polyvinyl alcohol</p><p>Macrogol 3350</p><p>Talc</p><p>Lecithin (contains soya oil) (E322)</p><p>Titanium dioxide (E171)</p><p>yellow iron oxide (E172)</p><p>yellow iron oxide (E172)</p><p>red iron oxide (E172)</p><p>Sunset Yellow FCF Aluminium Lake (E110)</p><p>Iron oxide black (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PE/PVDC Al Blister and OPA/AL/PVC Blister</p><p>Pack sizes: 7, 14, 28, 56, 98 and 280 film-coated tablets</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: 
SPIMACO 
AlQassim pharmaceutical plant 
Saudi Pharmaceutical Industries & Medical Appliance Corporation 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>